论文部分内容阅读
目的:了解恩替卡韦治疗慢性乙型肝炎患者免疫球蛋白及补体的变化。方法:采用流式细胞仪检测95例慢性乙型肝炎患者在使用恩替卡韦治疗前及80例健康对照组外周血免疫球蛋白的变化,采用Beckman-Coulter Immage 800免疫化学系统及其配套试剂测定血清补体C3和C4,用雅培化学发光法检测HBs Ag含量。结果:在治疗6个月结束时,95例患者肝功能明显好转,HBs Ag滴度下降前后对比有统计学意义(P<0.05),26例(27.3%)HBs Ag下降>500 IU/m L;恩替卡韦治疗前后Ig G、Ig M、Ig A水平对比有统计学意义(P<0.05);C3和C4水平在治疗前分别为(0.602±0.112)g/L和(0.113±0.075)g/L,治疗后分别为(1.201±0.156)g/L和(0.196±0.033)g/L(P<0.05)。结论:慢性乙型肝炎患者存在不同程度的细胞免疫功能低下,恩替卡韦治疗后能得到一定程度的纠正。
Objective: To understand the changes of immunoglobulin and complement in patients with chronic hepatitis B treated with entecavir. Methods: The changes of peripheral blood immunoglobulins in 95 patients with chronic hepatitis B before and after treatment with entecavir were detected by flow cytometry. Serum complement was detected by Beckman-Coulter Immage 800 immunochemistry system and its accessory reagents C3 and C4, using Abbott chemiluminescence detection of HBsAg content. Results: At the end of 6 months of treatment, the liver function of 95 patients improved obviously. The HBs Ag titer decreased significantly (P <0.05), and 26 cases (27.3%) HBs Ag decreased more than 500 IU / m L ; The levels of Ig G, Ig M and Ig A before and after entecavir treatment were statistically significant (P <0.05); the levels of C3 and C4 before treatment were (0.602 ± 0.112) g / L and (0.113 ± 0.075) g / L (1.201 ± 0.156) g / L and (0.196 ± 0.033) g / L respectively after treatment (P <0.05). Conclusion: There are different degrees of cellular immune dysfunction in patients with chronic hepatitis B, which can be corrected to some extent after entecavir treatment.